The European Commission has said it is “firmly committed to phasing out animal testing” as it launches a roadmap for chemical safety assessments. The latest statistics on animal use for the EU and Norway show over 9.1 million animals were used in scientific tests and experiments in the EU and Norway in 2023. This includes… Read More
Professor Mark Lewis, CEO of Myomaker Bio explores how animal testing is being reduced through a new era of drug development. Across the world, there is growing evidence that the long-standing reliance on animal testing in scientific research could be entering a period of significant change. For decades, scientists, regulators and… Read More
The Medicines and Healthcare products Regulatory Agency (MHRA) will offer early review of non-animal data in a decision supporting the government’s strategy to reduce animal testing in drug development. The move is intended to help drug developers make greater use of New Approach Methodologies (NAMs), hopefully giving developers… Read More
DDW Editor Reece Armstrong takes a look at three pieces of animal model research that are driving forward drug discovery. Animal models have been used as standard tools for clinical research for decades now, helping researchers bring treatments to market. Though the models have faced challenges in translating results seen… Read More
Dr Isaac Bentwich, Founder and CEO of Quris-AI examines the rise of alternative approaches to animal testing within drug discovery. Since the Federal Food, Drug, and Cosmetic Act of 1938, animal testing has served as the foundational model for biomedical research, offering scientists insights into disease mechanisms and drug safety. Read More
DDW’s Multimedia Editor Megan Thomas attended the Society for Neuroscience (SfN)’s Neuroscience 2024 in October 2024 in Chicago, US. Having published a general event roundup, here she unpacks the ‘Animals in Research’ panel: Lifesaving clinical advances stemming from animal research, which took place on Monday 7 October. Read More
Professor Andy Whiting, CEO of Nevrargenics, asks whether animal models should be used as the default regulatory requirement and explores the times to use them. Animal models (AMs) have generally been seen as useful for drug development and biomedical research for many years. They are assumed to closely mimic human… Read More
New survey findings have revealed that 77% of R&D professionals are not using in vitro cell-based alternatives to animal testing, and only 23% describe themselves as ‘very familiar’ with any kind of animal model alternative. More than 350 survey respondents participated in the survey by The… Read More
Charles River Laboratories International has launched its Alternative Methods Advancement Project (AMAP), an initiative focused on developing alternatives to reduce animal testing. The company has invested $200 million over the past four years to reduce the use of animal testing and has a five-year goal of… Read More
The latest sponsored DDW Sitting Down With podcast features Professor Jonathan Blackburn, Chief Scientific Officer of Sengenics, who discusses the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery… Read More
The latest sponsored DDW Sitting Down With podcast features Professor Jonathan Blackburn, Chief Scientific Officer of Sengenics, who discusses the advantages of functional protein microarrays, challenges to overcome for biomarker discovery, Sengenics’ new i-Ome Discovery… Read More
The latest sponsored DDW Sitting Down With podcast is now available. It features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 in relation to seizure liability as well as… Read More
The latest sponsored DDW Sitting Down With podcast features Ruth Roberts and Michael Morton, co-founders of ApconiX, and Dr Kimberly Rockley, ApconiX, who discuss novel alternative methods and the impact of the FDA Modernisation Act 2.0 in relation to seizure liability as well as talking about the importance… Read More
This is the latest episode of the free DDW narrated podcast, “Innovating now to reinvent the future of drug discovery”. It covers three articles written for Volume 23, Issue 2 – Spring 2022 of DDW. They are called “Predictive biomarkers in the… Read More
Dr Megan MacBride and Dr Caroline Horizny Mitchell, Taconic, examine recent changes to animal testing in drug design. Drug discovery and development is an arduous process that can cost upwards of $2.6 billion and take over 10 years. While the discovery phase – which includes target… Read More
Jantzen Sperry, PhD, Director of Scientific Operations at Certis Oncology looks at how the adoption of orthotopic PDX models can elevate the impact of cancer research and improve translation in oncology drug development. The recent passage of the FDA Modernization Act, which removed the requirement for… Read More
